PLMA_1170x120_10-8-21

Avella

Avella’s use of AdhereTech improves adherence

Avella’s use of AdhereTech improves adherence

PHOENIX — Avella Specialty Pharmacy’s Use of AdhereTech smart pill bottles improved adherence and generated one to two additional fills per patient per year across multiple specialty medications and diseases The specialty pharmacy uses the smart bottles for five specialty medications, in programs with four different pharmaceutical manufacturers. Averaged across all patients and programs from

Avella to distribute Braftovi and Mektovi

Avella to distribute Braftovi and Mektovi

PHOENIX —  Avella has announced that it will distribute Braftovi (encorafenib and Mektovi (binimetinib), a combination therapy recently FDA approved for patients for the treatment of patients with unresectable or metastatic melanoma. Metastatic melanoma is the most serious, life-threatening type of skin cancer and is associated with low survival rates overall. Approximately 9,000 people are expected to die of melanoma in 2018. There

Avella to improve access to Naloxone

Avella to improve access to Naloxone

PHOENIX — Avella has announced it will distribute naloxone, a powerful therapy used to treat opioid overdoses, as part of an innovative new program designed to improve access to the drug. The program allows individuals and family members in certain states to simply contact the pharmacy and order the drug by phone, with no physician